Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecBiohitOrionModulight

Latest content

ShowingAll content types

Herantis: Valuation is attractive again

Research 20.11.2025 klo 12.26 by Antti Siltanen
Herantis Pharma

Bioretec: Building a new beginning

Research 14.11.2025 klo 13.18 by Antti Siltanen
Bioretec

Biohit: Chilean cancer project raises long-term potential

Research 13.11.2025 klo 10.45 by Antti Siltanen
Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Nightingale strengthens its research offering through strategic partnership

Analyst Comment 05.11.2025 klo 16.59 by Antti Luiro, Antti Siltanen
Nightingale Health

Modulight Q3'25: Risks grew more than potential

Research 27.10.2025 klo 10.34 by Antti Siltanen
Modulight

Faron: The share price drops offers a chance to buy more

Research 24.10.2025 klo 08.36 by Antti Siltanen
Faron Pharmaceuticals

Nexstim Q3'25: Steady progress during the fall

Analyst Comment 23.10.2025 klo 10.01 by Antti Siltanen
Nexstim

Modulight Q3'25 preview: Quantum computing project shapes the quarter

Analyst Comment 22.10.2025 klo 09.21 by Antti Siltanen
Modulight

Faron's ESMO release complemented the main results reported previously

Analyst Comment 21.10.2025 klo 09.17 by Antti Siltanen
Faron Pharmaceuticals

Nexstim received diagnostic approval also in the US

Analyst Comment 13.10.2025 klo 08.57 by Antti Siltanen
Nexstim
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.